Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomic Valley BiotechBOM:539206 +1.00%57 EBITDA Margin % is 7.73% as of Mar. 2026, which is 67% below its 10-year median of 23.39. GuruFocus rates BOM:539206 with a GF Score™ of 57/100 and a GF Value™ of ₹12.94 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, Genomic Valley Biotech ranks better than 79.53% on this metric.
Genomic Valley Biotech (BOM:539206) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genomic Valley Biotech EBITDA Margin % Related Terms
Genomic Valley Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genomic Valley Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539206 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomic Valley Biotech (BOM:539206) has a EBITDA Margin % of 7.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genomic Valley Biotech and its competitors. This is 67% below median its historical median of 23.39. According to the industry distribution chart, Genomic Valley Biotech ranks #193 out of 943 companies in the Biotechnology industry, placing it in the top 20.5%.
Is Genomic Valley Biotech's EBITDA Margin % too high?
Genomic Valley Biotech's current EBITDA Margin % of 7.73% is 67% below median its 10-year median of 23.39. Based on the distribution chart, Genomic Valley Biotech ranks #193 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #193 out of 943 companies for EBITDA Margin %. This places Genomic Valley Biotech in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genomic Valley Biotech and its competitors. Genomic Valley Biotech's current EBITDA Margin % is 7.73%, which is 67% below median its own 10-year median of 23.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.94, compared to a current price of ₹29.29 — trading 126.4% above its estimated fair value. The current EBITDA Margin % is 7.73%, which is 67% below median its 10-year median of 23.39. Genomic Valley Biotech's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current EBITDA Margin % is 7.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹29.29 is trading 126.4% above its estimated GF Value™ of ₹12.94.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
EBITDA Margin %: 7.73% (67% below median its 10-year median of 23.39)
GF Value™: ₹12.94 vs. price of ₹29.29 (126.4% above fair value)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
57GF Score
Get the complete analysis for BOM:539206
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
